Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
Arthritis Care & Research · 2023-04 · 75 (4) · 743-748
DOI: 10.1002/acr.24850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 17.12.2022. Verfasst von April Jorge und 5 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston. Hauptthemen laut MEDLINE: Antirheumatic Agents, Venous Thromboembolism, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Canadian Institutes of Health Research, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Objective
We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
Methods
We conducted a nested case–control study within inception cohorts of SLE and RA patients using administrative health databases including the entire population of British Columbia, Canada. We identified cases with incident CV events, including myocardial infarction (MI), stroke, or venous thromboembolism (VTE). We matched each case with up to 3 controls on age, sex, and rheumatic disease. HCQ exposure was categorized by the time between the last HCQ prescription date covered and the index date as current use, recent use, remote use, or never used. We used conditional logistic regression to assess the association between HCQ exposure and CV events, using remote use as the reference group.
Results
We identified 10,268 cases and 29,969 controls. Adjusted conditional odd ratios (cORs) and 95% confidence intervals (95% CIs) for current HCQ use relative to remote use were 0.86 (0.77–0.97) for combined CV events, 0.88 (0.74–1.05) for MI, 0.87 (0.74–1.03) for stroke, and 0.74 (0.59–0.94) for VTE. Recent HCQ users and nonusers had similar odds of combined CV events as remote users (cORs 0.93, 95% CI 0.77–1.13 and 0.96, 95% CI 0.88–1.04, respectively).
Conclusion
In this nested case–control study of patients with SLE and RA, we found a reduced risk of overall CV events associated with current HCQ use, including reductions in VTE and trends toward reductions in MI and stroke. These findings suggest a possible cardiovascular preventative benefit of HCQ use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital, Boston.
- Massachusetts General Hospital, Boston, and Arthritis Research Canada, Richmond, British Columbia, Canada.
- Arthritis Research Canada and University of British Columbia, Vancouver, British Columbia, Canada.
ORCID-Profile: April Jorge, Diane Lacaille, J Antonio Avina-Zubieta
Förderung
- NIAMS NIH HHS
- Canadian Institutes of Health Research
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Rheumatology Research Foundation
Zitieren
APA
Jorge, A., Lu, N., Choi, H., Esdaile, J. M., Lacaille, D., & Avina-Zubieta, J. A. (2023). Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. Arthritis Care & Research, 75(4), 743-748. https://doi.org/10.1002/acr.24850
Vancouver
Jorge A, Lu N, Choi H, Esdaile JM, Lacaille D, Avina-Zubieta JA. Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. Arthritis Care & Research. 2023;75(4):743-748. doi:10.1002/acr.24850
BibTeX
@article{Jorge2023,
author = {Jorge, April and Lu, Na and Choi, Hyon and Esdaile, John M and Lacaille, Diane and Avina-Zubieta, J Antonio},
title = {Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis},
journal = {Arthritis Care & Research},
year = {2023},
volume = {75},
number = {4},
pages = {743--748},
doi = {10.1002/acr.24850}
}
EUVIMED